Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.

Overview of attention for article published in Proceedings of the National Academy of Sciences of the United States of America, February 1995

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

patent: 126 patents

Readers on

mendeley: 45 Mendeley

So far, Altmetric has seen 126 patents that reference this research output.

Combination of oncolytic virus with immune checkpoint modulators

Grant US-12622937-B2

United States of America

12 May 2026

ANTICANCER COMPOSITION COMPRISING TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND IMMUNE…

Application EP-4600365-A2

European Patent Office

13 Aug 2025

Recombinant herpes simplex virus for cancer immunotherapy

Grant US-12329794-B2

United States of America

17 Jun 2025

Antibodies and nucleotide sequences, and uses thereof

Grant US-12291569-B2

United States of America

06 May 2025

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 122 additional patents.